AI-generated data could change how clinical supply teams forecast demand, plan manufacturing, and manage inventory, but knowing when to trust those signals is the real challenge.
- Last-Mile Lessons For Depot-To-Site Delivery
- Expanded Expertise, Deeper Insight: Clinical Supply Leader Welcomes Two New Advisors
- The Hidden Cost Of The "Cheap" Comparator Drug: Why The Lowest Price Can Become The Most Expensive Choice In Clinical Trials
- Could Smarter Use of Clinical Supply Data Help Avoid Certain Protocol Amendments?
- The Silent Threat To Clinical Trials: Why Shelf-Life Management Can Determine Study Success
- CDMO Quality Oversight: How FDA And Pharma Leaders Are Rethinking Data, AI, And Culture
- AI Is Only As Good As The Data Behind Your Clinical Trial Supply Chain
- Five Places Where AI Stalls In Clinical Supply
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
When Protocol Amendments Meet RTSM: From Headache To High-Performance
Learn why an RTSM solution should be adaptive and flexible, and should help clinical trial teams uncover the best ways to handle protocol amendments.
-
Technology Solutions That Help Optimize Clinical Trial Distribution And Supply
Explore how interactive response technology (IRT) can solve some common challenges of manually managed clinical trials and how to find the best IRT solution that meets clinical trial requirements.
-
3 Reasons Sponsors Should Own The RTSM Vendor Relationship
Explore how direct management of study randomization and supply chains reduces communication delays, improves system design, and protects clinical data integrity from accidental unblinding.
-
Optimizing IRT For Clinical Supply Management
Experts speak on supply capabilities within interactive response technology (IRT) – how flexibility is important to functionality and who to involve and which questions to ask in optimizing IRT for clinical supply.
-
Advantages Of Robotic Aseptic Processing
Examine the robotic technologies poised to increase manufacturing flexibility and efficiency while minimizing risk when bringing biologics to market.
-
Sponsor Overcomes Hold And Steers Products Through Development
Uncover how a small-sized biotech company was able to resolve critical regulatory CMC deficiencies to meet FDA requirements.
-
5 Ways To Get Ready For IRT Regulatory Inspections
Preparing for a regulatory inspection during a clinical trial can be daunting. Learn about the importance of clear roles, audit trails, data integrity, and training, and get recommendations to help.
-
Biosample Tracking: A Consenting Dilemma
Biosample collection is an inevitable part of most clinical trials. Learn how sponsors should be tracking every sample back to the source so as to not violate compliance issues.
-
Ensure Seamless, Efficient Delivery Of Clinical Trial Materials Worldwide
Drug discovery companies, CROs, and CDMOs are under pressure to find supply management solutions that ensure delivery of clinical trial materials while navigating complex study designs and the regulatory landscape.
-
Bringing A Biosimilar For Oncology To Market: Injectable Packaging From Early Development To Commercialization
While in their early-stage development of a mAb biosimilar for oncology treatment, a large biopharmaceuticals company sought a packaging recommendation: a stopper to maintain high-quality standards.
- Root Causes, Part 1: When Trial Design Locks In Supply Risk
- Expanded Expertise, Deeper Insight: Clinical Supply Leader Welcomes Two New Advisors
- Could Smarter Use of Clinical Supply Data Help Avoid Certain Protocol Amendments?
- Can Your Operating Model Grow? Preparing Clinical Supply For What Comes Next
CATALENT CORNER
| Insights from Catalent's Clinical Supply Experts |
SPONSORED CONTENT
Impact Of Supplier Choice On APAC Clinical Trial Execution
Learn about strategies Asia-Pacific has become an increasingly complex and congested destination for clinical trials as local and global sponsors alike flock to the region to take advantage of its many benefits, including access to large patient pools. Choosing the right clinical packaging and supply chain partner to support these studies is critical and can vary significantly based upon what countries are involved and the types of services required.